(Q36493495)

14 August 2017

1 reference

title

The role of chemotherapy in the treatment of malignant astrocytomas (English)

1 reference

14 August 2017

1 reference

1

David Mathieu

1 reference

14 August 2017

2

David Fortin

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Canadian Journal of Neurological Sciences

14 August 2017

published in

1 reference

14 August 2017

volume

33

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

127-140

1 reference

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Vitamin D metabolites activate the sphingomyelin pathway and induce death of glioblastoma cells

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Matrix metalloproteinase inhibitors: a novel class of anticancer agents

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Chemotherapy in adult malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Retinoids in cancer treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Clinical studies with matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

[Sensitivity to etoposide of human malignant glioma cell lines. Mechanisms of action].

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Etoposide: four decades of development of a topoisomerase II inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Taxanes: an overview of the pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Penetration of etoposide into human malignant brain tumors after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Clinical pharmacokinetics and administration of established platinum drugs

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Superfractionation radiation therapy in the treatment of malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Temozolomide in patients with high grade gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Irinotecan therapy in adults with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Accelerated hyperfractionated radiotherapy for malignant gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Studies and perspectives of protein kinase C.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Expression of matrix metalloproteinase-2 in glial and neuronal tumor cell lines: inverse correlation with proliferation rate.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Isolation and characterization of human malignant glioma cells from histologically normal brain

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

No responses to oral etoposide in 15 patients with recurrent brain tumors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Tamoxifen as a potential treatment of glioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Cytotoxic effects of 1 alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Intravenous carboplatin for recurrent malignant glioma: a phase II study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Is necrosis helpful in the grading of gliomas? Editorial opinion

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Taxol: a novel investigational antimicrotubule agent

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Salvage chemotherapy with paclitaxel for recurrent primary brain tumors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: an in vitro phase II trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Chemosensitivity of glioma cells in vitro: a meta analysis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Histopathology, classification, and grading of gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Ongoing trials with matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Endostatin induces endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Clinical applications of anticancer drugs targeted to topoisomerase II

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Matrix metalloproteinase inhibitors in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

New drugs on the horizon: matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Matrix metalloproteinase inhibitors: applications in oncology.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

The clinical pharmacology of etoposide: an update

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Effects of vitamin D and retinoic acid on human glioblastoma cell lines.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Thalidomide in cancer: potential uses and limitations

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Matrix metalloproteinases and their biological function in human gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Platinum analogues in the treatment of recurrent high grade astrocytoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Anthracycline and anthraquinone anticancer agents: current status and recent developments

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Improving medical approaches to primary CNS malignancies--retinoid therapy and more.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Anti-angiogenic treatment strategies for malignant brain tumors

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602)

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

Thalidomide as an anti-angiogenic agent in relapsed gliomas

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100004881

7 January 2021

10.1017/S0317167100004881

Identifiers

DOI

0 references

1 reference